Niagen Bioscience has announced that the company has been granted US Patent No. 12,558,367, which covers the methods of use of nicotinamide riboside (NR) and derivatives in intravenous (IV) and injectable formulations.
Its claims cover aqueous formulations, various administration routes, specific administration parameters, select NR salt forms and the combined use of NR with other NAD+ precursors.
By expanding the company's intellectual property (IP) portfolio in this growing market segment, the patent supports new commercial opportunities and partnerships, enhancing the durability of Niagen Bioscience's product line.
Rob Fried, CEO of Niagen Bioscience, said: "This patent expands our intellectual property for our patented NR ingredient, Niagen, into IV and injectable delivery formats."
With expected protection through 2044, it supports Niagen's exclusivity in delivering a superior IV and injectable product with significantly faster delivery and improved comfort for patients across our expanding US clinic footprint.
Niagen Bioscience has developed a next-generation intravenous formulation of pharmaceutical-grade Niagen as part of its Niagen Plus product portfolio.
According to the company, this formulation is designed to support healthy ageing and longevity at the cellular level.
Compared to traditional NAD+ IV, the aqueous-based Niagen formulation allows for faster infusions and raises NAD+ levels more effectively, all while minimising the severe side effects associated with NAD+ IV.
This highlights the commercial importance of the newly issued patent.
Niagen Bioscience has said that it is dedicated to evaluating and exploring next-generation NAD+ precursors in the rapidly growing healthy ageing sector.
The company holds a strong portfolio of more than 100 patents, which protect its flagship ingredient, Niagen, recognised as the most effective and highest-quality NAD+ precursor available, as well as other NAD+ precursors.